Mochida Pharmaceutical Co., Ltd.

Details

2025/09/22

IR News

Notice Concerning Subscription to a Third-Party Allotment of Shares and the Acquisition of Shares of And Pharma Co., Ltd. (Making it an Equity-Method Affiliate)(PDF 207KB)
2025/08/18

Press Release

The NHI Drug Price Listing and Launch of LIALDA Tablets 600mg, a Treatment for Ulcerative Colitis, in Japan(PDF 189KB)
2025/08/01

IR News

[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2025(PDF 1,110KB)
2025/06/27

IR News

Notice Regarding Approval of the Continuation of the Policy on Large-Scale Share Acquisition (Takeover Response Policy) and Changes of Special Committee Member(PDF 214KB)
2025/06/24

Press Release

Mochida Obtained Approval for a Partial Change Application in Approved Matters of Ulcerative Colitis Treatment LIALDA to Add Dosage and Administration for Pediatric Patients and Obtained Marketing Approval for LIALDA Tablets 600mg(PDF 240KB)
2025/06/19

Press Release

Announcement of Approval of Epadel in Vietnam(PDF 195KB)
2025/06/02

IR News

NOTICE OF THE 87th ORDINARY GENERAL MEETING OF SHAREHOLDERS (PDF 433KB)
2025/05/15

IR News

FY2024 Financial Results Presentation (PDF 391KB)
2025/05/12

IR News

Notice Concerning Change of Representative Directors and Directors (PDF 207KB)
2025/05/12

IR News

Continuation of the Policy on Large-Scale Share Acquisition (Takeover Response Policy) (PDF 399KB)
2025/05/12

IR News

[Summary] Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (PDF 670KB)
2025/05/12

IR News

The Mochida Pharmaceutical Group’s “25-27 Medium-term Management Plan” Notice (PDF 383KB)
2025/03/26

Press Release

Announcement of Application for Manufacturing and Marketing Approval of Tocilizumab Biosimilar in Japan (PDF 77KB)
2025/02/07

IR News

[Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2024 (PDF 618KB)
2025/01/17

Press Release

Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 (PDF 190KB)
2025/01/15

Press Release

Announcement of positive topline results for RGB-19, a biosimilar to Tocilizumab (PDF 125KB)
2024/12/16

Press Release

Announcement of the Sales Partnership Agreement of Epadel in South Korea (PDF 62KB)
2024/11/25

Press Release

Announcement of Receiving ISO13485 Certification (PDF 79KB)
2024/11/07

IR News

FY2024 Q2 Financial Results Presentation (PDF 569KB)
2024/11/01

IR News

[Summary] Consolidated Financial Results for the Six Months Ended September 30, 2024 (PDF 774KB)
2024/10/31

Press Release

Distribution Rights Agreement for TYVASO DPI™, a Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease, in Japan (PDF 234KB)
2024/10/01

Press Release

Announcement of Change in Business Scheme of Insomnia Treatment QUVIVIQ® (PDF 64KB)
2024/09/24

Press Release

Announcement of Manufacturing and Marketing Approval of Insomnia Treatment QUVIVIQ® in Japan (PDF 133KB)
2024/09/24

Press Release

Mochida Obtained Approval for an Additional Indication of TREPROST® Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease in Japan (PDF 314KB)
2024/08/02

IR News

[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2024 (PDF 721KB)
2024/07/22

Press Release

Mochida Filed a Partial Change Application in Approved Matters of Ulcerative Colitis Treatment LIALDA® to Add Dosage and Administration for Pediatric Patients in Japan (PDF 306KB)
2024/07/16

Press Release

Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 (PDF 189KB)
2024/07/02

Press Release

Announcement of Submission of New Drug Application for Epadel in China (PDF 105KB)
2024/07/02

Press Release

Mochida Pharmaceutical Obtains 510(k) Clearance for "ReFeel®", a Material that Supports Nerve Regeneration, in the United States (PDF 220KB)
2024/05/31

IR News

NOTICE OF THE 86th ORDINARY GENERAL MEETING OF SHAREHOLDERS (PDF 412KB)
2024/05/16

IR News

FY2023 Financial Results Presentation (PDF 1,219KB)
2024/05/13

IR News

[Summary]Consolidated Financial Results for the Year Ended March 31, 2024 (PDF 736KB)
2024/02/05

IR News

[Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2023 (PDF 894KB)
2023/12/25

Press Release

Mochida Filed an Application for Approval of an Additional Indication for TREPROST® Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease or Combined Pulmonary Fibrosis and Emphysema, in Japan (PDF 291KB)
2023/11/02

IR News

[Summary] Consolidated Financial Results for the Six Months Ended September 30, 2023 (PDF 778KB)
2023/11/01

Press Release

Announcement of the Sales Partnership Agreement in Japan between Mochida and Shionogi regarding Insomnia Treatment Drug Daridorexant (PDF 169KB)
2023/10/31

Press Release

Announcement of Application for Manufacturing and Marketing Approval of Insomnia Treatment Daridorexant in Japan (PDF 81KB)
2023/08/04

IR News

[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2023 (PDF 677KB)
2023/06/05

IR News

NOTICE OF THE 85th ORDINARY GENERAL MEETING OF SHAREHOLDERS (PDF 342KB)
2023/05/15

IR News

[Summary]Consolidated Financial Results for the Year Ended March 31, 2023 (PDF 561KB)
2023/04/24

Press Release

The Launch of Treprost® Inhalation Solution, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 112KB)
2023/03/28

Press Release

The contract for the joint commercialization of HLC-001 in regenerative medicine products (PDF 227KB)
2023/03/22

Press Release

Senju initiated Phase III Clinical Trials in Japan for “SJP-0132” for the treatment of Dry Eye Disease The Clinical Trials use a novel compound discovered by Mochida and licensed to Senju (PDF 168KB)
2022/12/23

Press Release

Mochida Obtains Marketing Approval for Treprost® Inhalation Solution, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 110KB)
2022/05/20

Press Release

“MOVICOL® HD” Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan (PDF 232KB)
2022/05/13

IR News

The Mochida Pharmaceutical Group’s “22-24 Medium-Term Management Plan” (PDF 441KB)
2022/02/04

Press Release

Mochida files New Drug Application for MD-711, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 36KB)
2021/11/25

Press Release

The NHI Drug Price Listing and Launch of Adalimumab Biosimilar in Japan (PDF 178KB)
2021/04/01

IR News

The Mochida Pharmaceutical Group's “21-23 Medium-Term Management Plan” (PDF 309KB)
2020/05/27

Press Release

The NHI Drug Price Listing and Launch of DINAGEST Tablets 0.5mg, a Treatment for Dysmenorrhea (PDF 104KB)
2020/04/01

IR News

The Mochida Pharmaceutical Group’s “20-22 Medium-Term Management Plan” (PDF 183KB)
2020/01/23

Press Release

Mochida Obtains Marketing Approval in Japan for DINAGEST Tablets 0.5 mg for the Treatment of Dysmenorrhea (PDF 101KB)
2019/12/05

Press Release

Mochida Pharmaceutical Announce a License Agreement for the Co-development and Co-marketing of daridorexant, an Investigational Therapeutic Agent for Insomnia, in Japan (PDF 301KB)
2019/11/27

Press Release

The NHI Drug Price Listing and Launch of Teriparatide BS MOCHIDA, a Treatment for Osteoporosis, in Japan (PDF 171KB)
2019/09/20

Press Release

Mochida obtains marketing approval for teriparatide biosimilar in Japan (PDF 184KB)
2019/04/01

IR News

The Mochida Pharmaceutical Group’s “19-21 Medium-Term Management Plan” (PDF 98KB)
2019/02/08

Press Release

Mochida files application for marketing and manufacturing approval of the indication for dysmenorrhea for “Dinagest,” in Japan (PDF 37KB)
2018/11/29

Press Release

MOVICOL® Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan (PDF 211KB)
2018/09/21

Press Release

Marketing and Manufacturing Approval of Chronic Constipation Treatment “MOVICOL®” Obtained in Japan (PDF 164KB)
2018/07/09

Press Release

Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment“GOOFICE® 5mg Tablet” Published in The Lancet Gastroenterology & Hepatology (PDF 212KB)
2018/05/30

Press Release

The NHI Drug Price Listing and Launch of Etanercept Biosimilar in Japan (PDF 93KB)
2018/05/28

Press Release

PⅢ Clinical Study Data on Chronic Constipation Treatment“GOOFICE® 5mg Tablet” Will Be Presented at DDW2018 (PDF 180KB)
2018/04/19

Press Release

World’s First Bile Acid Transporter Inhibitor “GOOFICE® 5mg Tablet” Launched in Japan (PDF 247KB)
2018/04/02

IR News

The Mochida Pharmaceutical Group’s “18-20 Medium Term Management Plan” (PDF 114KB)
2018/01/19

Press Release

Mochida obtains marketing approval for etanercept biosimilar in Japan (PDF 107KB)
2018/01/19

Press Release

New drug approval of bile acid transporter inhibitor “GOOFICE® 5mg Tablet” for chronic constipation was obtained in Japan (PDF 138KB)
2017/11/27

Press Release

Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan (PDF 108KB)
2017/09/29

Press Release

Joint Development and Marketing Agreement for Chronic Constipation Treatment AJG555 in Japan Was Signed (PDF 34KB)
2017/04/03

IR News

The Mochida Pharmaceutical Group’s “17-19 Medium Term Management Plan” (PDF 80KB)
2017/03/28

Press Release

Distribution Rights Agreement for Tyvaso®, a Treatment for Pulmonary Arterial Hypertension, in Japan (PDF 41KB)
2017/02/01

Press Release

New Drug Application of AJG533 for chronic constipation was filed in Japan. (PDF 77KB)
2016/12/02

Press Release

Announcement of approval for an additional indication for therapeutic agent for endometriosis, “Dinagest Tab. / OD Tab.” in Japan (PDF 41KB)
2016/11/18

Press Release

The NHI Drug Price Listing and Launch of LIALDA®, a Once-Daily Treatment for Ulcerative Colitis (PDF 45KB)
2016/09/30

Press Release

EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce the results of phase 3 study of AJG533 for chronic constipation conducted in Japan ―Primary endpoint was met in patients with chronic constipation (PDF 42KB)
2016/09/30

Press Release

Revised agreement for the commercialization of TRAMCET® Combination Tablets for the relief of chronic non-cancer pain and pain after tooth extraction (PDF 60KB)
2016/09/28

Press Release

Mochida obtains marketing approval for LIALDA®, a Once-Daily Treatment for Ulcerative Colitis, in Japan (PDF 19KB)
2016/04/01

IR News

The Mochida Pharmaceutical Group’s “16-18 Medium Term Management Plan” (PDF 78KB)
2016/01/27

Press Release

Announcement of an application for approval of an additional indication for therapeutic agent for endometriosis, “Dinagest Tab. / OD Tab.” in Japan (PDF 14KB)
2015/11/20

Press Release

Announcement of an approval for an additional indication for the Anti-depressant, Lexapro® Tablets 10mg in Japan (PDF 56KB)
2015/10/30

Press Release

Mochida files New Drug Application for MD-0901, a Once-Daily Treatment for Ulcerative Colitis, in Japan (PDF 19KB)
2015/05/15

Press Release

Mochida announces Termination of License Agreement with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (PDF 14KB)
2015/04/01

IR News

The Mochida Pharmaceutical Group’s “15-17 Medium Term Management Plan” (PDF 112KB)
2014/04/01

IR News

The Mochida Pharmaceutical Group’s “14-16 Medium Term Management Plan” (PDF 113KB)
2013/04/02

IR News

The Mochida Pharmaceutical Group’s “13-15 Medium Term Management Plan” (PDF 91KB)
2012/09/28

Press Release

Mochida Pharmaceutical and Hospira Japan partner on distribution and co-promotion of oncology generic products in Japan (PDF 21KB)
2012/04/02

IR News

The Mochida Pharmaceutical Group’s “12-14 Medium Term Management Plan” (PDF 91KB)
2011/12/13

Press Release

Mochida announces License Agreement with Merck (PDF 19KB)
2011/10/03

IR News

The Mochida Pharmaceutical Group’s “11-13 Medium Term Management Plan” (PDF 64KB)
2011/07/21

Press Release

The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro® 10 mg (PDF 16KB)
2011/04/22

Press Release

Mochida receives an approval for an Anti-depressant, Lexapro® 10 mg in Japan (PDF 19KB)
2010/12/14

Press Release

Conclusion of Comprehensive License and Collaboration Agreement with Gedeon Richter concerning Biosimilar Product Portfolio (PDF 63KB)
2010/09/15

Press Release

Mochida files New Drug Application for an Anti-depressant, Escitalopram in Japan (PDF 55KB)
2010/04/13

Press Release

Mochida announces Termination of License Agreement with Wyeth (PDF 39KB)
2010/04/01

IR News

Overview of the Mochida Pharmaceutical Group’s “10-12 Medium Term Management Plan” (PDF 89KB)
2010/01/07

Press Release

Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan (PDF 35KB)
2009/04/30

Press Release

Conclusion of Distributorship Agreement Concerning Switch-OTC Drug for Hyperlipidemia Treatment, Epadel (PDF 14KB)
2009/04/01

IR News

Overview of the Mochida Pharmaceutical Group’s “09-11 Medium Term Management Plan” (PDF 11KB)
2009/01/16

Press Release

Mochida Concludes License Agreement for LIALDA® - A Once-Daily Treatment for Ulcerative Colitis (PDF 14KB)
2008/04/01

IR News

Overview of the Mochida Pharmaceutical Group’s “08-10 Medium Term Management Plan” (PDF 82KB)
2008/03/03

Press Release

Transfer of Marketing Authorizations and Distribution Rights for Bone Metabolism Marker “OSTEOMARK” and “OSTEOMARK NTx SERUM” (PDF 34KB)

Details